These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12235206)

  • 1. Lymphangiogenic gene therapy with minimal blood vascular side effects.
    Saaristo A; Veikkola T; Tammela T; Enholm B; Karkkainen MJ; Pajusola K; Bueler H; Ylä-Herttuala S; Alitalo K
    J Exp Med; 2002 Sep; 196(6):719-30. PubMed ID: 12235206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.
    Saaristo A; Veikkola T; Enholm B; Hytönen M; Arola J; Pajusola K; Turunen P; Jeltsch M; Karkkainen MJ; Kerjaschki D; Bueler H; Ylä-Herttuala S; Alitalo K
    FASEB J; 2002 Jul; 16(9):1041-9. PubMed ID: 12087065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
    Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
    Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the molecular pathogenesis and targeted treatment of lymphedema.
    Saaristo A; Karkkainen MJ; Alitalo K
    Ann N Y Acad Sci; 2002 Dec; 979():94-110. PubMed ID: 12543720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model for gene therapy of human hereditary lymphedema.
    Karkkainen MJ; Saaristo A; Jussila L; Karila KA; Lawrence EC; Pajusola K; Bueler H; Eichmann A; Kauppinen R; Kettunen MI; Yla-Herttuala S; Finegold DN; Ferrell RE; Alitalo K
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12677-82. PubMed ID: 11592985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
    Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S
    Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.
    Yoon YS; Murayama T; Gravereaux E; Tkebuchava T; Silver M; Curry C; Wecker A; Kirchmair R; Hu CS; Kearney M; Ashare A; Jackson DG; Kubo H; Isner JM; Losordo DW
    J Clin Invest; 2003 Mar; 111(5):717-25. PubMed ID: 12618526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin.
    Enholm B; Karpanen T; Jeltsch M; Kubo H; Stenback F; Prevo R; Jackson DG; Yla-Herttuala S; Alitalo K
    Circ Res; 2001 Mar; 88(6):623-9. PubMed ID: 11282897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
    Veikkola T; Jussila L; Makinen T; Karpanen T; Jeltsch M; Petrova TV; Kubo H; Thurston G; McDonald DM; Achen MG; Stacker SA; Alitalo K
    EMBO J; 2001 Mar; 20(6):1223-31. PubMed ID: 11250889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.
    Mäkinen T; Jussila L; Veikkola T; Karpanen T; Kettunen MI; Pulkkanen KJ; Kauppinen R; Jackson DG; Kubo H; Nishikawa S; Ylä-Herttuala S; Alitalo K
    Nat Med; 2001 Feb; 7(2):199-205. PubMed ID: 11175851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphangiogenic growth factors, receptors and therapies.
    Lohela M; Saaristo A; Veikkola T; Alitalo K
    Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane.
    Oh SJ; Jeltsch MM; Birkenhäger R; McCarthy JE; Weich HA; Christ B; Alitalo K; Wilting J
    Dev Biol; 1997 Aug; 188(1):96-109. PubMed ID: 9245515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth factor therapy and lymph node graft for lymphedema.
    Tervala TV; Hartiala P; Tammela T; Visuri MT; Ylä-Herttuala S; Alitalo K; Saarikko AM
    J Surg Res; 2015 Jun; 196(1):200-7. PubMed ID: 25777822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis.
    Karkkainen MJ; Petrova TV
    Oncogene; 2000 Nov; 19(49):5598-605. PubMed ID: 11114740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.
    Mäkinen T; Veikkola T; Mustjoki S; Karpanen T; Catimel B; Nice EC; Wise L; Mercer A; Kowalski H; Kerjaschki D; Stacker SA; Achen MG; Alitalo K
    EMBO J; 2001 Sep; 20(17):4762-73. PubMed ID: 11532940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of Vascular Endothelial Growth Factor-C156S in Therapeutic Lymphangiogenesis: A Systematic Review.
    Forte AJ; Boczar D; Huayllani MT; Anastasiadis PZ; McLaughlin S
    Lymphat Res Biol; 2022 Dec; 20(6):580-584. PubMed ID: 35501971
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular regulation of lymphangiogenesis and targets for tissue oedema.
    Karkkainen MJ; Jussila L; Ferrell RE; Finegold DN; Alitalo K
    Trends Mol Med; 2001 Jan; 7(1):18-22. PubMed ID: 11427983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K
    Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.
    Paavonen K; Mandelin J; Partanen T; Jussila L; Li TF; Ristimaki A; Alitalo K; Konttinen YT
    J Rheumatol; 2002 Jan; 29(1):39-45. PubMed ID: 11824969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.